ARTICLES BY ANITA BURRELL
-
Can Real-World Evidence Improve Market Access For Biosimilars In The U.S.?6/29/2018
A look at the role real-world evidence (RWE) can play in increasing the uptake of biosimilars in the U.S. market and some of the challenges in leveraging the potential of RWE.
-
How Recent Regulatory And Payer Developments Will Impact U.S. Biosimilar Access6/19/2018
In this second installment of a three-part series, industry stakeholders discuss recent developments in the U.S. marketplace from both the regulatory and payer viewpoints, with an emphasis on how these may lead to opportunities for biosimilar manufacturers.
-
Market Access Impediments: Where Should Biosimilars Go From Here?6/12/2018
In this first article of a three-part roundtable industry experts share their insights on the status of the market for biosimilars and explore some of the reasons for the difference between the U.S. and Europe.
-
How Should Biosimilar Companies Approach Real-World Evidence?4/24/2018
Real-world evidence (RWE) has become increasingly important for innovative manufacturers looking to convince reluctant payers that their new medicine has a place in patient care. Indeed, many claim the changing nature of the data landscape in healthcare will revolutionize the way we consider evidence, but does this apply to biosimilars? Is there a real need to look at data from actual clinical practice before or after market entry for these products?